Journal of Cancer Prevention is a multi-disciplinary journal that aims to promote an increased awareness of all aspects of cancer research that ultimately leads to cancer prevention. The journal publishes important original research articles, reviews/commentary, editorials, short communications, meeting reports, and letters to the editor that warrant prompt publication in the areas of carcinogenesis, chemoprevention, molecular epidemiology, and cancer biology. The journal content comprises basic, clinical and translational research with special attention given to molecular and cellular mechanisms of cancer chemopreventive agents as well as identification of novel risk factors and biomarkers of cancer. All submitted manuscripts are peer-reviewed and accepted only based on the premise that they have not been and will not be published elsewhere. The Journal of Cancer Prevention reserves the right to edit the language of papers accepted for publication for clarity and correctness and to make formal changes to ensure compliance with this journal.

Editorial Office Contact Information

National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Phone: +82-10-9065-7333, Fax: +82-64-702-2687, e-mail: journal@jcpjournal.org

• Researchers should be honest about their research. Researchers need to have a high ethical standard at all times during the research, in areas such as receiving funds for research, publishing research results, and fairly compensating participants. More specifically, research papers that are forged, altered, plagiarized, overlapped, and/or dishonest cannot be published either online or in a printed form and are not eligible for research funds.
  • (1) Forgery, Alteration, and Plagiarism
    1) Forgery: making up data or research results that do not exist.
    2) Alteration: fabricating research materials, equipment, or processes, or changing/deleting research results intentionally to distort research contents or results.
    3) Plagiarism: using others’ ideas, research (process and contents), and/or results without proper authorization or citation.
  • (2) Overapping Publication and Dishonest Research
    1) Publishing a paper that overlaps substantially with one published in other journals or public domain is prohibited.
    2) Multiple or duplicate publication can be allowed after a review from the Publication Council, if it is qualified under the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals (http://www.icmje.org/recommendations/). 3) The following is considered dishonest: either refusing to an authorship (without proper reasons) to a person who contributed, or giving credit to a person who did not contribute to publication.
• Studies involving human subjects and/or parts of human tissues should follow the Declaration of Helsinki (http://www.wma.net). Details are as follows:
  • (1) Researchers should fully explain the purpose and methods of research as well as any possible mental and physical harm that could occur during research participation. If they plan to publish the research results, these issues should be specified in the manuscript.
  • (2) Researchers cannot write down participants’ names or initials. In case of possible disclosure of participants’ identification through pictures of face or anything similar, researchers should receive written informed consent from the participants or their guardians.
  • (3) Researchers should receive an approval from Institutional Review Board and indicate it on the paper if they would like to publish the research results.
  • (4) Any research that deals with clinical trial should be registered to the primary national clinical trial registration site such as https://cris.nih.go.kr/cris/index.jsp, or other sites accredited by WHO or International Committee of Medical Journal Editor (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html).
• Studies using animals should follow general rules:
  • (1) Researchers should indicate what they did to minimize the pain or discomfort that experiment subjects went through.
  • (2) Researchers should indicate that they did not violate NIH guideline (NIH Guide for the Care and Use of Laboratory Animals).
  • (3) When necessary, the journal can ask for a written consent and an approval letter issued by Animal Ethics Committee.
• Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer).” Authors should define how they determined race or ethnicity and justify their relevance.
• Conflicts of interest or financial support should be indicated in the manuscript.
• Process for Managing Research and Publication Misconduct Journal of Cancer Prevention is part of Similarity Check, an initiative to help editors verify the originality of submitted manuscripts. Submitted manuscripts are scanned and compared with the Similarity Check database and iThenticate system (http://www.ithenticate.com). When the journal faces suspected cases of research and publication misconduct, such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts).
• How the Journal Handle Complaints and Appeals The policy of Journal of Cancer Prevention is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals.
  Who complains or makes an appeal? Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter via E-mail: journal@jcpjournal.org
  org. For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
  Who is responsible to resolve and handle complaints and appeals? The Editor, Editorial Board, or Editorial Office is responsible for them. A legal consultant or ethics editor may be able to help with the decision making.
  What may be the consequence of remedy? It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee of Publication Ethics (COPE).
• Corrections of Errors
  The journal will publish corrections when errors could affect the interpretation of data or information. When the error is made by the author, the term “Corrigendum” will be used; when the error is made by the Publisher, the term “Erratum” will be used.

All authors must have made significant intellectual contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted, (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Each author should have participated sufficiently in the work to take public responsibility for the content. Participation solely in the acquisition of funds or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship.

Prevention of research misconduct by co-author(s) with personal connections
Those under 19-year-old or family members (spouse, children, and relatives as far as fourth cousins) are called “people with personal connections.”

• 1) A paper involving co-author(s) with personal connections should demonstrate their(his/her) contribution to the research and the manuscript.
• 2) A paper including co-author(s) with personal connections should be submitted with “Disclosure Form for Author(s) with Personal Connections” or “Pre-release Publication Form for Author(s) with Personal Connections.”

The authors hereby transfer, convey, and assign all copyrights in the Article to the Korean Society of Cancer Prevention. Authors should complete and upload the Copyright Transfer Agreement and Conflict of Interest Disclosure Form (http://www.jcpjournal.org/submission/File/Copyright_form.pdf) signed by all authors, as part of submission.

There are 5 types of papers in Journal of Cancer Prevention.
Authors should follow the below guidelines for manuscript length:

• Original Articles
  • 250 word limit for the abstract
  • 5,000 words (excluding references and figure legends)
  • 60 references
  • 8 or fewer tables and/or figures (8 in total)
• Reviews/Commentaries
  • 250 word limit for the abstract
  • 6,000 words of text
  • 120 references
  • 8 or fewer tables and/or figures (8 in total)
• Short Communications
  • 250 word limit for the abstract
  • 3,500 words (excluding references and figure legends)
  • 40 references
  • 5 or fewer tables and/or figures (5 in total)
• Editorials

  Editorials will be paired with the most important articles of the issue and will be solicited at the provisional acceptance of an article.

  • 1,000 words of text
  • 20 references
  • 2 or fewer tables and figures
  • Not divided into sections
• Letters to the Editor
  • 600 words of text
  • No more than 5 references, the first of which should be the original article the author refers to
  • No tables or figures unless approved by the Editor
  • The title is “Running title of the original article”- Letter
  • Must be submitted within 6 months of the original article’s publication.
• Meeting Reports
  • Should focus on the new scientific discoveries and key developments/applications presented and discussed at a specific conference
  • Must be relevant to the subject of the journal
  • Abstract summarizing an overview of the meeting required (200 world limit)
  • No more than 50 references (If more citations are needed, consult the Editor)
  • Images or photos are acceptable at Editor’s discretion
  • Conflict of Interest should be disclosed

• Manuscript Submission Manuscripts should be submitted via the Journal of Cancer Prevention online manuscript and review system at “http://www.jcpjournal.org/” by a corresponding author. Before submission, please carefully read the Author Check List.
  • (1) Copyright Transfer Agreement and Conflict of Interest Disclosure
    The authors can find the form in the journal web site. This form should be signed by all authors and uploaded.
  • (2) Open Researcher and Contributor ID (ORCID)
    All authors’ ORCID numbers are required for submission. The ORCID number can be obtained from http://orcid.org.
  • (3) Cover Letter
    The cover letter is required as part of submission. The cover letter should include the summary and importance of the manuscript. Also, the corresponding author must give written assurance that neither the submitted materials nor their portions have been published previously or are under consideration for publication by this or other journals or books. At the end of the cover letter, the name and an e-mail address of the corresponding author for the manuscript should be provided.
    
    It is highly recommended that the authors have their manuscript checked through accredited professional English editing services prior to submission of their manuscript. The authors can suggest the names, affiliations, and e-mail addresses of 3 to 5 potential referees. After the manuscript is submitted, the corresponding author will receive an acknowledgement with a manuscript number, confirming receipt. Authors will be able to track the status of their manuscripts via the online system.
    Revised manuscripts should also be submitted via the Journal online system. When submitting the revised manuscript, please provide point-by-point responses to the reviewers’ comments by listing all the changes made. In addition, the authors should provide a marked version of the revised manuscript in which all the changes are indicated in color.
• Manuscript Preparation The journal follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals (http://www.icmje.org/recommendations/) and Good Publication Practice Guidelines for Medical Journals 2nd (https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=7). Authors are recommended to consult the Medical Terminology Book (http://term.kma.org/).
  • (1) Manuscript File Formats
    For submission and review, an acceptable manuscript file format is Microsoft Word (.doc or .docx). Use of Arial or Times New Roman with a 12-point font size is recommended for all text. All pages of a submission should be numbered and double spaced. Line numbers should be included throughout the main body of the manuscript. Do not submit your manuscript in a PDF format.
  • (2) Title Page
    Title: The main title of the manuscript should be consise while informative. Titles are often used in information-retrieval systems. Do not use abbreviations and formulae in the title.
    Running title: 60 characters or less, reflecting the main title and content of the manuscript.
    Author names and affiliations: List authors in the order of their first name, middle initial (if applicable), and then surname (last name). Present the authors’ affiliation (where the actual work was done) in the order of the authors. Place the superscript number(s) before each affiliation and the same number(s) immediately after the author’s name. The affiliations should contain information on the name of the institution and location (city/town, zip code and country name).
    Corresponding author: Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address, the complete postal address, and Open Researcher and Contributor ID (ORCID). Contact details must be kept up to date by the corresponding author.
  • (3) Abstract
    The second page of every manuscript must contain only the Abstract, which should be a single paragraph not exceeding 250 words. Abstracts exceeding 250 words may be truncated in MEDLINE. The Abstract should be comprehensible to readers before they have read the paper, and abbreviations and reference citations should be avoided.
  • (4) Key Words Select up to 5 key words from the Medical Subject (MeSH) Headings from Index Medicus and list them below the abstract.
  • (5) Main Text The text for most of the original research articles should include Introduction, Materials and Methods, Results, and Discussion. Results and Discussion sections may be combined. Also, the Acknowledgments and Conflicts of Interest sections could be added.
    Introduction: The rationale for the study should be summarized and pertinent background material should be outlined. The introduction should not contain either results or conclusions.
    Materials and Methods: Materials and Methods should be described in sufficient detail so that another investigator could repeat the work. The names of manufacturers of equipment and non-generic drugs should be given. Statistical methods used should be outlined. Ethical guidelines for human or animal study should be described and approval of institutional human research review committee or animal welfare committee should be indicated.
    Results: Results should be presented in a logical sequence in the text, tables and illustrations, and repetitive presentation of the same data in different forms should be avoided. Extensive interpretation should be reserved for the Discussion section. Number figures and tables according to the order of citation in the text.
    Discussion: The Discussion section should be concise and provide an interpretation of the results in relation to previously published works and to the experimental system at hand. It should not contain extensive repetition of contents of the Results section or reiteration of the Introduction.
    Acknowledgments: The source of financial grants and personal assistances should be acknowledged. The contribution of colleagues or institutions should also be acknowledged, if applicable.
    Conflicts of Interest: Include in this section conflicts of interest disclosure. The corresponding author of an article is asked to inform the Editor of the authors’ potential conflicts of interest possibly influencing their interpretation of data. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. A potential conflict of interest should be disclosed in the manuscript even when the authors are confident that their judgments have not been influenced in preparing the manuscript. The disclosure form should be the same as the ICMJE form Disclosure for Potential Conflicts of Interest (http://www.icmje.org/conflicts-of-interest/).
  • (6) References [JCP Endnote Style file]
    Referencing should be complied with the Journal of Cancer Prevention system. In the text, references should be cited using brackets ‘[ ]’ and Arabic numerals in the order in which they appear. The journal names should be abbreviated in accordance with the style used in PubMed. If cited only in tables or figure legends, number them according to the first identification of the table or figure in the text. In the reference list, the references should be numbered and listed in the same order of their appearance in the text. List all the authors up to six. If more than six, list the first six and add “et al.” Reference to unpublished data and personal communications should not appear in the list but can be mentioned in the text only. References should be listed in the following forms:
    Articles: Myung SK, Yang HJ, Kwak SM, Jung HS, Oh SW, Park CH. Efficacy of vitamin and antioxidant supplements in pre-vention of esophageal cancer: meta-analysis of randomized controlled trials. J Cancer Prev 2013;2:1-10.
    Books: Miller RG Jr. Simultaneous statistical inference. Springer-Verlag, 1981.
    Book chapter: Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In: Cooper CS, Grover PC, eds. Handbook of Experimental Pharmacology. Springer-Verlag, pp 63-95, 1990.
    Website: Centers for Medicare & Medicaid Services. CMS proposals to implement certain disclosure provisions of the Affordable Care Act. http://www.cms.gov/apps/media/press/factsheet.asp?Counter=4221 (Accessed January 30, 2012).
    Epub ahead of print: Steinbrook R, Ross JS. “Transparency reports” on industry payments to physicians and teaching hospitals [published online ahead of print February 14, 2012]. JAMA. doi:10.1001/jama.2012.211
  • (7) Tables
    Each table must be simple and typed on a separate page with its heading above it. Explanatory matter is placed in footnotes below the tabular matter and not included in the heading. All nonstandard abbreviations are explained in the footnotes. Footnotes should be indicated by superscripts a, b, and c etc. The word “number” should be abbreviated as “n” to express the number of samples or subjects. For example, it should be written down as (n=24). Statistical measures such as SD or SE(M) should be identified. If the statistical significance is indicated by using a P value, the ‘P’ should be capitalized (upper-case) and italicized (e.g., *P < 0.05; **P < 0.01; ***P < 0.001). Each table is referred in the text consecutively and numbered according to order of citation. The tables and its legend/footnotes should be understandable without reference to the text.
  • (8) Figure Legends
    Figure legends should be typed double-spaced on a separate sheet in the manuscript text. Type legends with Arabic numerals corresponding to the Figure number. Symbols, arrows and letters indicating parts of illustrations should be explained in the legend. If the statistical significance is indicated by using a P value, the ‘P’should be capitalized (upper-case) and italicized (e.g., *P < 0.05; **P < 0.01; ***P < 0.001).
  • (9) Figures
    Figures should be consecutively numbered according to order of citation in the text, using Arabic numerals. Each panel (part) in figures should be listed as A, B, or C at the left upper corner of each panel. Figures should be submitted as separate files. Figure format is individualized as follows: Photographic images should be submitted in TIFF or JPEG format. It should have minimum width of 100 mm, a minimum resolution of 300 dpi. Neither compression nor change of the color mode should be made. Line-arts (graphs and illustrations) should be submitted in native PPT preferred) including editable figure elements, vector files (e.g., EPS) or TIFF files (at least 900 dpi with a minimum width of 100 mm). Provide figures in a finished form.
  • (10) Supplementary Data
    Supporting materials which are not essential in the full text, but would nevertheless benefit the reader, can be published as online only supplementary data. Supplementary data should be submitted for review, in a separate file from the manuscript. Each type of supplementary material should be numbered independently (Figure S1, Figure S2, Table S1, etc.) and referred to in the main text. Supplementary files supplied will be published online alongside the electronic version of the article in Journal of Cancer Prevention website.
  • (11) Recommended File Sizes
    We recommend individual file sizes of not exceeding 1 MB, with the total size for all files not exceeding 5 MB (not including any video files).
  • (12) Units of Measurement
    Authors should express all measurements in conventional units, with System International (SI) units given in parentheses throughout the text. Figures and tables should use conventional units, with conversion factors given in legends or footnotes. Some examples of units frequently used are: mL (millilter), mL (microliter), h (hour), min (minute), s (second). Use the gravity unit ‘g’ in italic. The unit of temperature is the degree Celsius (°C). There is no space between the temperature unit and the number (e.g., 37°C). Likewise, no space is placed between the number and percentile unit (%).
  • (13) Abbreviations
    Journal of Cancer Prevention provides a list of the official abbreviations. It appears in the Journal and its website. Otherwise, any unofficial abbreviations used more than 3 times should be defined for the first use in the text.

All submissions will undergo an unbiased and timely double bline peer review process. A submitted manuscript is first checked for its format and adherence to the aims and scope of the journal and then sent to at least two reviewers to receive their comments. The acceptance criteria for all papers include the quality and originality of the research and its scientific significance. Acceptance of the manuscript is decided based on the critiques and recommended decision of the reviewers. The reviewers’ comments are sent to the corresponding author by e-mail. The corresponding author must indicate the alterations that have been made in response to the reviewers’ comments and suggestions, point by point. Failure to submit the revised manuscript within 4 weeks of the editorial decision, unless approved for extension of the submission, is regarded as a withdrawal. A final decision on acceptance/rejection for publication is forwarded to the corresponding author from the editor.

After acceptance of the article, corresponding authors will receive PDF proofs by e-mail. Authors must check the proofs and return any corrections within 48 hours. The main content of an article cannot be changed during galley proof reading. Request for erratum to change authors or acknowledgement will not be accepted after publication.

Publication in Journal of Cancer Prevention involves the payment of a fixed publication fee. After acceptance, authors will be charged 300,000 KRW (300 USD) for each manuscript.